Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nevro May Lose Pain-Stim Patent Case Against Boston Scientific

Executive Summary

A California judge has issued a tentative ruling favoring Boston Scientific in patent litigation between the company and Nevro. But the negative impact of the ruling on Nevro may be limited, analysts say.

You may also be interested in...



Mixed Final Ruling In Nevro, Boston Sci Patent Spat

A California federal judge delivered a mixed verdict in a patent dispute between Nevro Corp. and Boston Scientific. The court said that some of Nevro's claims were patent-eligible, but further ruled that Boston Scientific had not infringed those patents.

Market Intel: NANS 2018: Positive Data Intensifies Spinal-Cord Stim's Big-Four Rivalry

The market for spinal cord stimulation (SCS) systems, used for treating chronic debilitating pain, is expanding relentlessly, and companies like Abbott Laboratories, Medtronic, Boston Scientific and Nevro are all vying to gain more market share with their respective technologies. At this year's annual meeting of the North American Neuromodulation Society (NANS) in Las Vegas, physicians were presented with the latest clinical evidence backing these innovations. This article looks at the overall SCS market, discusses study findings presented at NANS and the latest innovations. It also provides insights from two established pain management specialists on factors they think will drive SCS technologies forward.

NWW: Studies Back Nevro Pain Treatment, FTC Blesses Resonetics Nitinol Deal, Genetic Test Identifies Best RDN Patients

This week, studies supported Nevro’s spinal cord stimulation therapy and a VRx system that helps reduce pain; the American Medical Association found inconsistent insurance coverage of digital therapeutics; and Geneticure announced a cheek-swab test to identify which patients are most likely to benefit from renal denervation.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT122989

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel